A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson’s, ...

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

GLP-1 drugs also improve blood flow to the heart ... and therefore a positive effect in Alzheimer’s disease and Parkinson’s disease,” note the authors. More than 100 preclinical research ...

For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced ...

A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

Ozempic, Wegovy, Saxenda, Trulicity: These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease ... risks of GLP-1 weight-loss drugs ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

GLP-1 drugs also improve blood flow to the heart and act directly ... memory formation and therefore a positive effect in Alzheimer’s disease and Parkinson’s disease,” note the authors. More than 100 ...

"Our findings demonstrate that GLP1-RAs can lead to fewer cardiovascular events, less progression of kidney disease, and lower health care costs," study co-senior author Dr. Ildiko Lingvay said.